Regeneron Pharmaceuticals Inc. buy Oppenheimer Holdings Inc.
Start price
02.02.26
/
50%
€639.20
Target price
02.02.27
€728.50
Performance (%)
3.97%
Price
06.02.26
€664.60
Summary
This prediction is currently active. With a performance of 3.97%, the BUY prediction by Oppenheimer_Holdings for Regeneron Pharmaceuticals Inc. is trending in the right direction. This prediction currently runs until 02.02.27. The prediction end date can be changed by Oppenheimer_Holdings at any time. Oppenheimer_Holdings has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | 3.97% |
| iShares Core DAX® | -0.197% |
| iShares Nasdaq 100 | -3.612% |
| iShares Nikkei 225® | 1.176% |
| iShares S&P 500 | -0.825% |
Comments by Oppenheimer_Holdings for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $865.00 price target on the stock, up previously from $750.00.
Ratings data for REGN provided by MarketBeat
Stopped prediction by Oppenheimer_Holdings for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€768.80
06.11.24
06.11.24
€933.10
06.11.25
06.11.25
-26.66%
07.11.25
07.11.25
